
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HPV Vaccine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : University Medical Centre Ljubljana
Deal Size : Inapplicable
Deal Type : Inapplicable
HPV Infections and Vaccine Attitudes In Slovenian Women Post Vaccination
Details : HPV Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : HPV Vaccine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : University Medical Centre Ljubljana
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Rabin Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Keytruda
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 30, 2025
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Rabin Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nonavalent Hpv Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nonavalent Hpv Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Papillomavirus Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Nonavalent Hpv Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NOUS-209,MVA-209-FSP,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Nouscom AG
Deal Size : Undisclosed
Deal Type : Collaboration
Details : NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : NOUS-209,MVA-209-FSP,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Nouscom AG
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ATG-037,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Antengene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemoth...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 26, 2022
Lead Product(s) : ATG-037,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Antengene
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is i...
Product Name : Lynparza
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DR30303,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Zhejiang Doer Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : DR30303,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Zhejiang Doer Biologics
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
Product Name : Lynparza
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Olaparib,Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PMC-309,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : PharmAbcine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : PMC-309,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : PharmAbcine
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Nykode Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 06, 2022
Lead Product(s) : VB10.16,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Nykode Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
